Patents Assigned to Merck
  • Antiviral aryl-amide phosphodiamide compounds
    Patent number: 10736908
    Abstract: Compounds of Formula (I): (Formula (I)) and their pharmaceutically acceptable salts are useful for the inhibition of HIV reverse transcriptase. The compounds may also be useful for the prophylaxis or treatment of infection by HIV and in the prophylaxis, delay in the onset or progression, and treatment of AIDS. The compounds and their salts can be employed as ingredients in pharmaceutical compositions, optionally in combination with other antiviral agents, immunomodulators, antibiotics or vaccines.
    Type: Grant
    Filed: October 20, 2017
    Date of Patent: August 11, 2020
    Assignees: MERCK SHARP & DOHME CORP., IDENIX PHARMACEUTICALS LLC
    Inventors: Jean-Laurent Paparin, Houcine Rahali, Aurélien Salanson, Daniel Da Costa, David Dukhan, Timothy J. Hartingh, Izzat Raheem, John Schreier
  • Diagnostic anti-PD-L1 antibody and use thereof
    Patent number: 10738120
    Abstract: The present invention provides for an antibody or antigen-binding fragment thereof which binds to an epitope within human PD-L1 with high specificity and reproducibility. The inventive antibody or antigen-binding fragment thereof may be used in assessing PD-L1 expression in tissue samples to aid in patient stratification. The present invention further provides methods of producing the inventive antibody.
    Type: Grant
    Filed: September 20, 2017
    Date of Patent: August 11, 2020
    Assignees: Merck Patent GmbH, Pfizer Inc.
    Inventors: Claudia Wilm, Klaus Schneider, Heike Dahmen
  • Cyclic di-nucleotide compounds as STING agonists
    Patent number: 10738074
    Abstract: A class of polycyclic compounds of general formula (II), of general formula (II?), or of general formula (II?), wherein Base1, Base2, Y, Ya, Xa, Xa1, Xb, Xb1, Xc, Xc1, Xd, Xd1, R1, R1a, R2, R2a, R3a, R4, R4a, R5, R6, R6a, R7, R7a, R8, and R8a are defined herein, that may be useful as inductors of type I interferon production, specifically as STING active agents, are provided. Also provided are processes for the synthesis and use of compounds.
    Type: Grant
    Filed: August 11, 2016
    Date of Patent: August 11, 2020
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Michael D. Altman, Brian Andresen, Wonsuk Chang, Matthew Lloyd Childers, Jared N. Cumming, Andrew Marc Haidle, Timothy J. Henderson, James P. Jewell, Min Lu, Alan B. Northrup, Ryan D. Otte, Tony Siu, Benjamin Wesley Trotter, Quang T. Truong
  • Thiadiazoloquinoxaline derivatives
    Patent number: 10738240
    Abstract: The present invention relates to thiadiazoloquinoxaline derivatives of the formula I, in which R11, R12, A11, A12, A21, A22, Z11, Z12, Z21, Z22, W, X11, X12, r and s have the meanings indicated in Claim 1, to processes and intermediates for the preparation thereof, to the use of the compounds of the formula I for optical, electro-optical and electronic purposes, in particular in liquid-crystal media and in devices for regulating the passage of energy from an outside space into an inside space, and to these LC media and the devices comprising these media.
    Type: Grant
    Filed: April 13, 2016
    Date of Patent: August 11, 2020
    Assignee: Merck Patent GmbH
    Inventors: Peer Kirsch, Andreas Ruhl, Susann Gunst, Michael Junge, Ursula Patwal, Mila Fischer
  • Chromane-substituted tetracyclic compounds and uses thereof for the treatment of viral diseases
    Patent number: 10738062
    Abstract: The present invention relates to novel Chromane-Substituted Tetracyclic Compounds of Formula (I) and pharmaceutically acceptable salts thereof, wherein A, A?, R2 R3, R4 and R5 are as defined herein. The present invention also relates to compositions comprising a Chromane-Substituted Tetracyclic Compound, and methods of using the Chromane-Substituted Tetracyclic Compounds for treating or preventing HCV infection in a patient.
    Type: Grant
    Filed: August 14, 2017
    Date of Patent: August 11, 2020
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Wensheng Yu, Joseph A. Kozlowski, Ling Tong, Craig A. Coburn, Bin Hu, Bin Zhong, Jinglai Hao, Dahai Wang
  • Electronic component including molecular layer
    Patent number: 10741778
    Abstract: An electronic component (10) comprising a plurality of switching elements (1) which comprise, in this sequence, a first electrode (16), a molecular layer (18) bonded to a substrate, and a second electrode (20), where the molecular layer essentially consists of molecules (M) which contain a connecting group (V) and an end group (E) having a polar or ionic function, is suitable as memristive device for digital information storage.
    Type: Grant
    Filed: December 8, 2015
    Date of Patent: August 11, 2020
    Assignee: MERCK PATENT GMBH
    Inventors: Peer Kirsch, Qiong Tong, Andreas Ruhl, Marc Tornow, Achyut Bora
  • POLYMERIZABLE COMPOUNDS AND THE USE THEREOF IN LIQUID-CRYSTAL DISPLAYS
    Publication number: 20200248078
    Abstract: The present invention relates to polymerizable compounds, to processes and intermediates for the preparation thereof, to liquid-crystal media comprising them, and to the use of the polymerizable compounds and liquid crystalline media for optical, electro-optical and electronic purposes, in particular in liquid crystalline displays, especially in liquid crystalline displays of the polymer sustained alignment type.
    Type: Application
    Filed: April 22, 2020
    Publication date: August 6, 2020
    Applicant: MERCK PATENT GMBH
    Inventors: Qiong TONG, Nico SCHWEBEL, Constanze BROCKE, Kaja Christina DEING, Julian VOGT, Elisabeth MEYER
  • LIQUID CRYSTAL MEDIUM AND LIQUID CRYSTAL DEVICE
    Publication number: 20200248077
    Abstract: The invention relates to a medium comprising at least 60% of one or more compounds of formula I wherein R11, R12, MG11, MG12 and Sp1 have the meaning given herein below, to the use of such media in liquid crystal devices, in particular in flexoelectric liquid crystal devices, and to a flexoelectric liquid crystal device comprising a liquid crystal medium according to the present invention.
    Type: Application
    Filed: November 18, 2016
    Publication date: August 6, 2020
    Applicant: Merck Patent GmbH
    Inventors: Simon SIEMIANOWSKI, Konstantin SCHNEIDER
  • BENZIL MONOKETALS AND THE USE THEREOF
    Publication number: 20200247916
    Abstract: The present invention relates to the use of hydrophilic compounds of the formula I as photopolymerisation initiators of polymerisable substance mixtures which comprise unsaturated compounds, or for the photochemical crosslinking of linear polymers, in which the parameters have the meaning indicated in Claim 1, to sealants for liquid-crystal displays which comprise the hydrophilic photoinitiators, to novel hydrophilic photoinitiators of the formula I, and to the liquid-crystal displays produced using these sealants.
    Type: Application
    Filed: October 5, 2016
    Publication date: August 6, 2020
    Applicant: Merck Patent GmbH
    Inventors: Peer KIRSCH, Qiong TONG, Alexander HAHN, Leo WEEGELS, Steffen GNAUCK, Sven SCHUEPFER, Peter LEONHARD, Claudia ENDERS
  • ARYL AND HETEROARYL ETHER DERIVATIVES AS LIVER X RECEPTOR BETA AGONISTS, COMPOSITIONS, AND THEIR USE
    Publication number: 20200247754
    Abstract: In its many embodiments, the present invention provides certain substituted aryl and heteroaryl ether compounds of the Formula (I): and pharmaceutically acceptable salts thereof, wherein X, R1, R2, R3, L, R4, L1, Q, and R5 are as defined herein. The novel compounds of the invention, and pharmaceutically acceptable compositions comprising a compound thereof, are useful as Liver X-? receptor (LXR?) agonists, and may be useful for treating or preventing pathologies related thereto. Such pathologies include, but are not limited to, inflammatory diseases and diseases characterized by defects in cholesterol and lipid metabolism, such as Alzheimer's disease.
    Type: Application
    Filed: October 9, 2017
    Publication date: August 6, 2020
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Michael T. Rudd, Zhaoyang Meng, Jenny Wai, David Jonathan Bennett, Edward J. Brnardic, Nigel J. Liverton, Shawn J. Stachel, Yongxin Han, Paul Tempest, Jiuxiang Zhu, Xuewang Xu, Bin Zhu
  • FORMULATION HAVING CONTROLLED, DELAYED RELEASE OF ACTIVE INGREDIENT
    Publication number: 20200246270
    Abstract: The present invention relates to novel pharmaceutical formulations which have controlled, delayed release of active ingredient, and to a process for the preparation of such formulations. The invention additionally relates to the use of these novel pharmaceutical administration forms as medicaments for the treatment of diseases which require delayed release of the active ingredient, such as hypertension, or asthmatic diseases.
    Type: Application
    Filed: April 21, 2020
    Publication date: August 6, 2020
    Applicant: Merck Patent GmbH
    Inventors: Finn BAUER, Thorsten WEDEL, Guenter MODDELMOG, Gudrun BIRK, Roberto OGNIBENE, Dieter LUBDA
  • Deep eutectic solvents and/or ionic liquids in cell culture media
    Patent number: 10731126
    Abstract: The present invention relates to cell culture media compositions comprising deep eutectic solvents and/or ionic liquids.
    Type: Grant
    Filed: May 2, 2016
    Date of Patent: August 4, 2020
    Assignee: Merck Patent GmbH
    Inventors: Jochen Bastian Sieck, Michael Howard Rayner, Joerg Von Hagen, Claudia Knack
  • Benzo[b]thiophene compounds as STING agonists
    Patent number: 10730849
    Abstract: Compounds of general formula (Ia), compounds of general formula (Ia?), compounds of general formula (Ib), compounds of general formula (Ib?), compounds of general formula (I), compounds of general formula (I?), and their pharmaceutically acceptable salts, wherein R1, R2, R3, R4, R5, R6, R8, R9, X1, X2, and X3 are defined herein, that may be useful as inductors of type I interferon production, specifically as STING active agents, are provided. Also provided are processes for the synthesis and use of compounds of the disclosure.
    Type: Grant
    Filed: July 16, 2019
    Date of Patent: August 4, 2020
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Michael D. Altman, Brandon D. Cash, Wonsuk Chang, Jared N. Cumming, Andrew M. Haidle, Timothy J. Henderson, James P. Jewell, Matthew A. Larsen, Rui Liang, Jongwon Lim, Min Lu, Ryan D. Otte, Tony Siu, Benjamin Wesley Trotter, Sriram Tyagarajan
  • Formulations of luminescent compounds
    Patent number: 10734587
    Abstract: The present invention relates to a formulation comprising organic materials for the production of organic electronic devices having a low failure rate.
    Type: Grant
    Filed: February 9, 2015
    Date of Patent: August 4, 2020
    Assignee: Merck Patent GmbH
    Inventors: Amir Hossain Parham, Philipp Stoessel, Christof Pflumm, Anja Jatsch, Joachim Kaiser, Anna Hayer
  • Beta-Hydroxyketones as topical active ingredients for the prevention or treatment of photodermatoses
    Publication number: 20200237685
    Abstract: The present invention relates to specific ?-hydroxyketones of the formula (I) for use in the prevention and/or treatment of photodermatoses and to the use of specific ?-hydroxyketones of the formula (I) as active ingredient in typical compositions for the prevention and/or non-therapeutic treatment of photodermatoses, in particular of polymorphic light eruption.
    Type: Application
    Filed: April 15, 2020
    Publication date: July 30, 2020
    Applicant: Merck Patent GmbH
    Inventors: Christophe CAROLA, Lilia HEIDER, Marina LEFORT, Hansjuergen DRILLER
  • PROCESS FOR THE PRODUCTION OF HOLLOW PLASTIC ARTICLES BY ROTATIONAL MOLDING POLYMERIC COMPOUNDS IN A ROTOMOLD
    Publication number: 20200238579
    Abstract: The present invention relates to a process for the production of hollow plastic articles in a rotational molding process as well as to hollow plastic articles made by such a process, in particular to a process for the production of hollow plastic articles which exhibit a colored surface exhibiting striking pearlescent or metallic effects.
    Type: Application
    Filed: November 21, 2016
    Publication date: July 30, 2020
    Applicant: Merck Patent GmbH
    Inventor: Scott AUMANN
  • PHARMACEUTICAL PREPARATION
    Publication number: 20200237733
    Abstract: The present invention relates to a solid pharmaceutical preparation of 3-Fluoro-4-[7-methoxy-3-methyl-8-(1-methyl-1H-pyrazol-4-yl)-2-oxo-2,3-dihydro-imidazo[4,5-c]quinolin-1-yl]-benzonitrile, a method of making same, and medical uses thereof.
    Type: Application
    Filed: August 8, 2018
    Publication date: July 30, 2020
    Applicant: Merck Patent GmbH
    Inventors: Simon GEISSLER, Stefan SCHILLER, Meike HARMS, Holger KUBAS, Markus WEIGANDT, Michael LANGE
  • NOVEL SUBSTITUTED PHENYLOXETANE AND PHENYLTETRAHYDROFURAN COMPOUNDS AS INDOLEAMINE 2,3-DIOXYGENASE (IDO) INHIBITORS
    Publication number: 20200239423
    Abstract: Disclosed herein is a compound of formula (I), or a pharmaceutically acceptable salt thereof: (Formula (I)). Also disclosed herein are uses of a compound disclosed herein in the potential treatment or prevention of an IDO-associated disease or disorder. Also disclosed herein are compositions comprising a compound disclosed herein. Further disclosed herein are uses of a composition in the potential treatment or prevention of an IDO-associated disease or disorder.
    Type: Application
    Filed: October 4, 2018
    Publication date: July 30, 2020
    Applicant: MERCK SHARP & DOHME CORP.
    Inventors: Catherine M. White, Meredeth Ann McGowan, Yongxin Han, Nunzio Sciammetta
  • Materials for electronic devices
    Patent number: 10727413
    Abstract: The invention relates to phenanthrene compounds comprising one or more arylamino groups. Said compounds can be used in electronic devices, in particular OLED's.
    Type: Grant
    Filed: February 9, 2015
    Date of Patent: July 28, 2020
    Assignee: Merck Patent GmbH
    Inventors: Teresa Mujica-Fernaud, Elvira Montenegro, Jochen Pfister
  • Materials for organic electroluminescent devices
    Patent number: 10723722
    Abstract: The present invention relates to materials for organic electroluminescent devices, in particular carbazolyl compounds substituted by electron-deficient heteroaryl groups, for use as triplet matrix materials in organic electroluminescent devices, for example the compounds of formula (1). The invention further relates to a process for preparing the compounds of the invention and to electronic devices comprising these.
    Type: Grant
    Filed: October 11, 2016
    Date of Patent: July 28, 2020
    Assignee: Merck Patent GmbH
    Inventors: Amir Hossain Parham, Aurélie Ludemann, Dominik Joosten, Tobias Grossmann, Jonas Valentin Kroeber